Abstract: The present invention relates to a method of treating agitation in a human patient with dementia, comprising administering to the human patient with dementia in need thereof a pharmaceutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or hydrate thereof to treat agitation, wherein R1-R4 are defined herein: wherein the human patient has at least an about 20% reduction in their symptom of agitation, relative to the patient prior to administration of the compound of formula (I).

Abstract: The present invention provides methods of maintaining stable remission or stable response achieved by a patient with depression following administration of a therapeutically effective amount of esketamine during an initial administration phase, comprising continuing administration of a therapeutically effective amount of esketamine for at least five months during a subsequent administration phase. The present invention also provides methods for the long term treatment of depression in a patient, comprising administering to the patient in need of the treatment a clinically proven safe and clinically proven effective therapeutically effective amount of esketamine for at least six months. In some embodiments, the depression is major depressive disorder or treatment resistant depression.

Abstract: The present invention provides methods of maintaining stable remission or stable response achieved by a patient with depression following administration of a therapeutically effective amount of esketamine during an initial administration phase, comprising continuing administration of a therapeutically effective amount of esketamine for at least five months during a subsequent administration phase. The present invention also provides methods for the long term treatment of depression in a patient, comprising administering to the patient in need of the treatment a clinically proven safe and clinically proven effective therapeutically effective amount of esketamine for at least six months. In some embodiments, the depression is major depressive disorder or treatment resistant depression.

Abstract: The present invention provides methods of maintaining stable remission or stable response achieved by a patient with depression following administration of a therapeutically effective amount of esketamine during an initial administration phase, comprising continuing administration of a therapeutically effective amount of esketamine for at least five months during a subsequent administration phase. The present invention also provides methods for the long term treatment of depression in a patient, comprising administering to the patient in need of the treatment a clinically proven safe and clinically proven effective therapeutically effective amount of esketamine for at least six months. In some embodiments, the depression is major depressive disorder or treatment resistant depression.

Abstract: A method for treating depression, anhedonia, or fatigue in a subject comprises administering an agent that blocks binding of IL-23 to IL-23 receptor, for example, an anti-IL-23 antibody or an antigen-binding fragment thereof that may comprise a heavy chain variable region and a light chain variable region of SEQ ID NO:106 and SEQ ID NO:116, respectively.

Abstract: The present invention is directed to, inter alia, methods and kits for the treatment of depression (preferably, treatment resistant depression), or for the treatment of depression in a suicidal patient, and/or for the treatment and/or prevention of suicidality (e.g. suicidal ideations) comprising administering esketamine according to certain dosing regimens.

Abstract: Provided herein are methods and compositions for the treatment of depression and anxiety. The compositions comprise scopolamine, or an analog thereof, and can optionally include one or more psychoactive agents. Further provided is an inhaler comprising scopolamine, or an analog thereof, in a pharmaceutically acceptable carrier.